Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Advanced Functional Materials

• Publication date

  2015-05-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1002/adfm.201404629PMID 26097445PMCID PMC4469082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.

  2014cited by this paper
• Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients

  2014cited by this paper
• Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery

  2014cited by this paper
• Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

  2014cited by this paper
• Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of siRNA Cancer Therapeutics

  2014cited by this paper
• Trastuzumab emtansine: mechanisms of action and drug resistance

  2014cited by this paper
• A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer

  2013cited by this paper
• A comparison of thiolated and disulfide-crosslinked polyethylenimine for nonviral gene delivery.

  2013cited by this paper
• Independent versus cooperative binding in polyethylenimine-DNA and Poly(L-lysine)-DNA polyplexes.

  2013cited by this paper
• Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

  2013cited by this paper
• Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma

  2013cited by this paper
• Delivery materials for siRNA therapeutics.

  2013cited by this paper
• Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

  2013cited by this paper
• A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.

  2013cited by this paper
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

  2013cited by this paper
• Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.

  2013cited by this paper
• Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?

  2013cited by this paper
• Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

  2013cited by this paper
• The Business of RNAi Therapeutics in 2012

  2012cited by this paper
• Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

  2012cited by this paper
• A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

  2012cited by this paper
• Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs

  2012cited by this paper
• Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery

  2012cited by this paper
• Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles.

  2012cited by this paper
• Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

  2012cited by this paper
• Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane

  2012cited by this paper
• Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis

  2012cited by this paper
• Differential expression of syndecan-1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cells.

  2011cited by this paper
• Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies

  2011cited by this paper
• RNA interference in the clinic: challenges and future directions

  2011cited by this paper
• Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

  2011cited by this paper
• Preparation, characterization, and modeling of carbon nanofiber/epoxy nanocomposites

  2011cited by this paper
• Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

  2011cited by this paper
• Physicochemical characterization and in vitro hemolysis evaluation of silver nanoparticles.

  2011cited by this paper
• Using functional genetics to understand breast cancer biology.

  2010cited by this paper
• RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells

  2010cited by this paper
• Running Title Page Running Title : Enhanced gene transfer and antimicrobial activity

  2010cited by this paper
• Strategies in the design of nanoparticles for therapeutic applications

  2010cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• Ferumoxytol: A New Intravenous Iron Preparation for the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease

  2010cited by this paper
• Novel Cationic Lipids with Enhanced Gene Delivery and Antimicrobial Activity

  2010cited by this paper
• Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells.

  2009cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• How Location Governs Toll‐Like Receptor Signaling

  2009cited by this paper
• The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

  2009cited by this paper
• Determinants of Cytokine Induction by Small Interfering RNA in Human Peripheral Blood Mononuclear Cells

  2008cited by this paper
• siRNA stabilization prolongs gene knockdown in primary T lymphocytes

  2008cited by this paper
• Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells

  2007cited by this paper
• Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

  2007cited by this paper
• Mesoporous Silica Nanoparticles for Drug Delivery and Biosensing Applications

  2007cited by this paper
• The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells.

  2007cited by this paper
• Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

  2007cited by this paper
• Inaugural Article: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

  2007cited by this paper
• Synthesis of poly(ethylene glycol) (PEG)-grafted colloidal silica particles with improved stability in aqueous solvents.

  2007cited by this paper
• Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

  2006cited by this paper
• Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes.

  2006cited by this paper
• The silent treatment: siRNAs as small molecule drugs

  2006cited by this paper
• HER2 therapy: Molecular mechanisms of trastuzumab resistance

  2006cited by this paper
• Gene delivery with low molecular weight linear polyethylenimines

  2005cited by this paper
• Polymers for DNA Delivery

  2005cited by this paper
• Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors

  2004cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Toll-like receptors in innate immunity.

  2004cited by this paper
• Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine.

  2003cited by this paper
• Intracellular route and transcriptional competence of polyethylenimine-DNA complexes.

  2002cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• The druggable genome

  2002cited by this paper
• HER2 as a prognostic and predictive marker for breast cancer.

  2001cited by this paper
• 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.

  2000cited by this paper
• Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

  2000cited by this paper
• A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.

  1995cited by this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Her2 Breast Cancer Therapies: a Review in Order To

  year unknowncited by this paper

• Interpreting the Theranostic Applications of Alumina and Silica Substrates in Cancer

  2026cites this paper
• Engineering mesoporous silica nanoparticles for cancer immunotherapy: mechanistic insights, therapeutic synergies, and translational roadmap

  2026cites this paper
• Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges

  2025cites this paper
• Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity

  2025cites this paper
• Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases

  2025cites this paper
• Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics

  2025cites this paper
• Engineered PD-L1 nanoregulators for enhanced tumor immunotherapy.

  2025cites this paper
• Advances in nanocarriers for targeted drug delivery and controlled drug release.

  2025cites this paper
• Construction and application of macrophage-based extracellular drug-loaded delivery systems.

  2025cites this paper
• BIO-NANOMATERIALS: PROMISING ANTICANCER PROPERTIES AND TREATMENT STRATEGIES

  2025cites this paper
• Nanoparticulate systems for combination therapies of lung cancer: A review

  2025cites this paper
• Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

  2025cites this paper
• Design of oxide nanoparticles for biomedical applications

  2025cites this paper
• Smart Mesoporous Silica Nanoparticles in Cancer: Diagnosis, Treatment, Immunogenicity, and Clinical Translation.

  2025cites this paper
• Evaluation of anticancer efficacy of survivin si-RNA functionalized combined drug-loaded mesoporous silica nanoparticles in a lung cancer mouse model

  2025cites this paper
• Engineering Covalent Aptamer Chimeras for Enhanced Autophagic Degradation of Membrane Proteins.

  2025cites this paper
• Glutamine modified lipid nanoparticles loaded with GPX4 siRNA for cervical cancer targeting.

  2025cites this paper
• The Landscape of Nanoparticle-based siRNA Delivery and Therapeutic Development.

  2024cites this paper
• Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications

  2024cites this paper
• Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers.

  2024cites this paper
• The past to the current advances in the synthesis and applications of silica nanoparticles

  2024cites this paper
• Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

  2024cites this paper
• Mechanistic Insights into Cisplatin Response in Breast Tumors: Molecular Determinants and Drug/Nanotechnology-Based Therapeutic Opportunities.

  2024cites this paper
• Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies

  2024cites this paper
• Harnessing Immunomodulatory Polymers for Treatment of Autoimmunity, Allergy, and Transplant Rejection.

  2024cites this paper
• Multi‐synergistic chemotherapeutic drug assemblies to activate colorectal cancer immunotherapy by modulating the multilevel immunosuppressive characteristics

  2024cites this paper
• Target Reprogramming the 3′UTR of Tumor‐Suppressor Genes by a siRNA Composite Nanoparticle for Glioblastoma Therapy

  2024cites this paper
• A comprehensive perspective of trastuzumab-based delivery systems for breast cancer treatment

  2024cites this paper
• RNAi-Based Therapy: Prospect as Cancer Treatment

  2024cites this paper
• Chemically Modified Platforms for Better RNA Therapeutics.

  2024cites this paper
• Silicon-containing nanomedicine and biomaterials: materials chemistry, multi-dimensional design, and biomedical application.

  2024cites this paper
• Trend in biodegradable porous nanomaterials for anticancer drug delivery.

  2023cites this paper
• Recent Advances in Engineering Carriers for siRNA Delivery.

  2023cites this paper
• Nanotechnology Applications in Breast Cancer Immunotherapy.

  2023cites this paper
• Bioinspired Spatiotemporal Management toward RNA Therapies.

  2023cites this paper
• A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches

  2023cites this paper
• Engineered Silica Nanoparticles for Nucleic Acid Delivery

  2023cites this paper
• Engineered mesoporous silica nanoparticles, new insight nanoplatforms into effective cancer gene therapy.

  2023cites this paper
• Mesoporous silica-based nanocarriers with dual response to pH and ROS for enhanced anti-inflammation therapy of 5-Demethylnobiletin against psoriasis-like lesions.

  2023cites this paper
• Nanomedicine in cancer therapy

  2023cites this paper
• Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification

  2023cites this paper
• Porphyrin Cholesterol Conjugates for Enhanced Photodynamic Immunotherapy toward Lung Cancer.

  2023cites this paper
• Macrophage Membrane‐Coated Nanoparticles Sensitize Glioblastoma to Radiation by Suppressing Proneural–Mesenchymal Transformation in Glioma Stem Cells

  2023cites this paper
• Nanomedicine

  2023cites this paper
• Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment

  2023cites this paper
• Non-viral gene therapy using RNA interference with PDGFR-α mediated epithelial-mesenchymal transformation for proliferative vitreoretinopathy

  2023cites this paper
• Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy

  2023cites this paper
• Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC.

  2022cites this paper
• Synthesis of hierarchical silica zeolites for heterogenous catalysis and adsorption

  2022cites this paper
• Aptamer‐siRNA chimeras: Promising tools for targeting HER2 signaling in cancer

  2022cites this paper
• Strategies to assemble therapeutic and imaging molecules into inorganic nanocarriers

  2022cites this paper
• Exploitation of High Tumour GSH Levels for Targeted siRNA Delivery in Rhabdomyosarcoma Cells

  2022cites this paper
• Chemically engineered mesoporous silica nanoparticles-based intelligent delivery systems for theranostic applications in multiple cancerous/non-cancerous diseases

  2022cites this paper
• Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

  2022cites this paper
• Nanomedicine for the Delivery of RNA in Cancer

  2022cites this paper
• Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications

  2022cites this paper
• Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis.

  2022cites this paper
• In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response

  2021cites this paper
• Mitochondria-targeted mesoporous silica nanoparticles noncovalently modified with triphenylphosphonium cation: physicochemical characteristics, cytotoxicity and intracellular uptake.

  2021cites this paper
• Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature

  2021cites this paper
• Stellate porous silica based surface-enhanced Raman scattering system for traceable gene delivery

  2021cites this paper
• Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine

  2021cites this paper
• Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies

  2021cites this paper
• Stimuli-responsive mesoporous silica nanoparticles: A custom-tailored next generation approach in cargo delivery.

  2021cites this paper
• Bio-based nanomaterials for cancer therapy

  2021cites this paper
• Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers

  2021cites this paper
• Harnessing pH-Sensitive Polycation Vehicles for the Efficient siRNA Delivery.

  2021cites this paper
• Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

  2021cites this paper
• Strategies of Cell Signaling and Critical Focus on Etiology of Hepatocellular Carcinoma

  2021cites this paper
• Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature.

  2021cites this paper
• Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature

  2021cites this paper
• Sustained doxorubicin delivery system to breast tumor cancer cell based on a novel cationic molecularly imprinted polymer

  2021cites this paper
• Cancer nanomedicine based on polyethylenimine-mediated multifunctional nanosystems

  2021cites this paper
• Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis

  2021cites this paper
• Mesoporous silica-biopolymer-based systems in drug delivery applications

  2021cites this paper
• RNAi-based combination therapies

  2021cites this paper
• Hollow structures as drug carriers: Recognition, response, and release

  2021cites this paper
• Aptamer-conjugated mesoporous silica nanoparticles for simultaneous imaging and therapy of cancer

  2020cites this paper
• Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy

  2020cites this paper
• Nanoarchitectured Structure and Surface Biofunctionality of Mesoporous Silica Nanoparticles

  2020cites this paper
• Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.

  2020cites this paper
• Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles

  2020cites this paper
• HER-2/neu and MYC gene silencing in breast cancer: therapeutic potential and advancement in nonviral nanocarrier systems.

  2020cites this paper
• Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer

  2020cites this paper
• Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

  2020cites this paper
• Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy

  2020cites this paper
• Silica-Based Gene Delivery Systems: From Design to Therapeutic Applications

  2020influential citation
• Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications

  2020cites this paper
• Application of mesoporous silica nanoparticles for drug delivery to cancer cells

  2020cites this paper
• Small interfering RNA for cancer treatment: overcoming hurdles in delivery

  2020cites this paper
• Preparation and Applications of Organo-Silica Hybrid Mesoporous Silica Nanoparticles for the Co-Delivery of Drugs and Nucleic Acids

  2020cites this paper
• Recent advances in HER2-targeted delivery for cancer therapy.

  2020cites this paper
• Role of charge reversal in the hemo/immunocompatibility of polycationic gene delivery systems.

  2019cites this paper
• Systemic Delivery of Small Interfering RNA Therapeutics: Obstacles and Advances

  2019cites this paper
• Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles

  2019cites this paper
• Nanomaterials-Based siRNA Delivery: Routes of Administration, Hurdles and Role of Nanocarriers

  2019cites this paper
• Prolonged Antimicrobial Activity of PMMA Bone Cement with Embedded Gentamicin-Releasing Silica Nanocarriers.

  2019cites this paper
• Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.

  2019cites this paper
• Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.

  2019cites this paper
• Role of Cholesterol Conjugation in the Antibacterial Photodynamic Therapy of Branched Polyethylenimine-Containing Nanoagents.

  2019cites this paper